An anonymous reader quotes a report from STAT: The Food and Drug Administration on Friday approved the world's first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder. The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations -- ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up. The FDA decision comes three weeks after regulators in the U.K. were the first to clear the drug. Approval in the European Union is expected next year. The FDA is also expected to rule on exa-cel as a treatment for beta thalassemia, another inherited blood disorder, by March 30.

The FDA on Friday also approved another sickle cell treatment, a gene therapy from Bluebird Bio called Lyfgenia. Patients will now have the option of two cutting-edge therapies that provide potentially curative benefits. Scientists Emmanuelle Charpentier and Jennifer Doudna published their first CRISPR paper just over a decade ago. In 2020, the research won the pair a Nobel Prize. Reflecting on the approval of Casgevy, Charpentier told STAT via email that she was "excited and pleased" for what it means for patients and their families.

The Biden administration is threatening to cancel the patents of some costly medications to allow rivals to make their own more affordable versions. The Associated Press reports: Under a plan announced Thursday, the government would consider overriding the patent for high-priced drugs that have been developed with the help of taxpayer money and letting competitors make them in hopes of driving down the cost. In a 15-second video released to YouTube on Wednesday night, President Joe Biden promised the move would lower prices. "Today, we're taking a very important step toward ending price gouging so you don't have to pay more for the medicine you need," he said.

White House officials would not name drugs that might potentially be targeted. The government would consider seizing a patent if a drug is only available to a "narrow set of consumers," according to the proposal that will be open to public comment for 60 days. Drugmakers are almost certain to challenge the plan in court if it is enacted. [...] The White House also intends to focus more closely on private equity firms that purchase hospitals and health systems, then often whittle them down and sell quickly for a profit. The departments of Justice and Health and Human Services, and the Federal Trade Commission will work to share more data about health system ownership.

While only a minority of drugs on the market relied so heavily on taxpayer dollars, the threat of a government "march-in" on patents will make many pharmaceutical companies think twice, said Jing Luo, a professor of medicine at University of Pittsburgh. "If I was a drug company that was trying to license a product that had benefited heavily from taxpayer money, I'd be very careful about how to price that product," Luo said. "I wouldn't want anyone to take my product away from me."

Researchers at Tohoku University in Japan found that wasabi improves both short- and long-term memory. CBS News reports: Rui Nouchi, the study's lead researcher and an associate professor at the school's Institute of Development, Aging and Cancer, told CBS News the results, while based on a limited sample of subjects without preexisting health conditions, exceeded their expectations. "We knew from earlier animal studies that wasabi conferred health benefits," he said in an interview from his office in northeast Japan. "But what really surprised us was the dramatic change. The improvement was really substantial."

The main active component of Japanese wasabi is a biochemical called 6-MSITC, a known antioxidant and anti-inflammatory known to exist in only trace amounts elsewhere throughout the plant kingdom, Nouchi said. The double-blind, randomized study involved 72 healthy subjects, aged 60 to 80. Half of them took 100 milligrams of wasabi extract at bedtime, with the rest receiving a placebo. After three months, the treated group registered "significant" boosts in two aspects of cognition, working (short-term) memory, and the longer-lasting episodic memory, based on standardized assessments for language skills, concentration and ability to carry out simple tasks. No improvement was seen in other areas of cognition, such as inhibitory control (the ability to stay focused), executive function or processing speed.

Subjects who received the wasabi treatment saw their episodic memory scores jump an average of 18%, Nouchi said, and scored on average 14% higher than the placebo group overall. The researchers theorized that 6-MSITC reduces inflammation and oxidant levels in the hippocampus, the area of the brain responsible for memory function, and boosts neural plasticity. Compared with the control group, the study said, subjects dosed with wasabi "showed improved verbal episodic memory performance as well as better performance in associating faces and names, which is often the major memory-related problem in older adults." But here's the rub: most of the "wasabi" you order at sushi restaurants is made of ordinary white horseradish, dyed green. "Genuine wasabi must be consumed fresh, with the stubbly rhizome, or stem of the plant, grated tableside just before eating," notes the report. "On the plus side, just a small dab offers the same benefits as the capsule supplements used in the Tohoku study, or 0.8 milligrams of 6-MSITC."

The study has been published in the journal Nutrients.

schwit1 shares a report from the New York Post: A landmark study out of the University of Adelaide and University of Essex has found that living in a private rental property accelerates the biological aging process by more than two weeks every year. The research found renting had worse effects on biological age than being unemployed (adding 1.4 weeks per year), obesity (adding 1 week per year), or being a former smoker (adding about 1.1 weeks). University of Adelaide Professor of Housing Research Emma Baker said private renting added "about two-and-a-half weeks of aging" per year to a person's biological clock, compared to those who own their homes.

"In fact, private rental is the really interesting thing here, because social renters, for some reason, don't seem to have that effect," Professor Baker told the ABC News Daily podcast. She said the security of social renting -- aka public housing -- and homeownership has compared to people living with an end-of-lease date on their calendars. "When you look at big studies of the Australian population, you see that the average rental lease is between six and 12 months," she said. "So even if you have your lease extended, you still are living in that slight state of kind of unknowingness, really not quite secure if your lease is actually going to be extended or not." "We think that that is one of the things that's contributing to loss of years, effectively."

Traumatic memories had their own neural mechanism, brain scans showed, which may help explain their vivid and intrusive nature. From a report: At the root of post-traumatic stress disorder, or PTSD, is a memory that cannot be controlled. It may intrude on everyday activity, thrusting a person into the middle of a horrifying event, or surface as night terrors or flashbacks. Decades of treatment of military veterans and sexual assault survivors have left little doubt that traumatic memories function differently from other memories. A group of researchers at Yale University and the Icahn School of Medicine at Mount Sinai set out to find empirical evidence of those differences.

The team conducted brain scans of 28 people with PTSD while they listened to recorded narrations of their own memories. Some of the recorded memories were neutral, some were simply "sad," and some were traumatic. The brain scans found clear differences, the researchers reported in a paper published on Thursday in the journal Nature Neuroscience. The people listening to the sad memories, which often involved the death of a family member, showed consistently high engagement of the hippocampus, part of the brain that organizes and contextualizes memories. When the same people listened to their traumatic memories -- of sexual assaults, fires, school shootings and terrorist attacks -- the hippocampus was not involved.

[...] Indeed, the authors conclude in the paper, "traumatic memories are not experienced as memories as such," but as "fragments of prior events, subjugating the present moment." The traumatic memories appeared to engage a different area of the brain -- the posterior cingulate cortex, or P.C.C., which is usually involved in internally directed thought, like introspection or daydreaming. The more severe the person's PTSD symptoms were, the more activity appeared in the P.C.C. What is striking about this finding is that the P.C.C. is not known as a memory region, but one that is engaged with "processing of internal experience," Dr. Schiller said.

The U.S. Food and Drug Administration is reviewing a cutting-edge therapy called exa-cel that could potentially cure people of sickle cell disease, a painful and deadly disease with no universally successful treatment. "If approved, exa-cel, made by Boston-based Vertex Pharmaceuticals and the Swiss company CRISPR Therapeutics, would be the first FDA-approved treatment that uses genetic modification called CRISPR," reports CNN. From the report: CRISPR, or clustered regularly interspaced short palindromic repeats, is a technology researchers use to selectively modify DNA, the carrier of genetic information that the body uses to function and develop. [...] The new exa-cel treatment under FDA consideration can use the patient's own stem cells. Doctors would alter them with CRISPR to fix the genetic problems that cause sickle cell, and then the altered stem cells are given back to the patient in a one-time infusion.

In company studies, the treatment was considered safe, and it had a "highly positive benefit-risk for patients with severe sickle cell disease," Dr. Stephanie Krogmeier, vice president for global regulatory affairs with Vertex Pharmaceuticals Incorporated, told the panel. Thirty-nine of the 40 people tested with the treatment did not have a single vaso-occlusive crisis, which means the misshapen red blood cells block normal circulation and can cause moderate to severe pain. It's the top reason patients with sickle cell go to the emergency room or are hospitalized. Before the treatment, patients experienced about four of these painful crises a year, resulting in about two weeks in the hospital.

The FDA sought the independent panel's advice, in part, because this would be the first time the FDA would approve a treatment that uses CRISPR technology, but Dr. Fyodor Urnov, a professor in the Department of Molecular and Cell Biology at the University of California, Berkeley, reminded the committee CRISPR has been around for 30 years and, in that time, scientists have learned a lot about how to use it safely. "The technology is, in fact, ready for primetime," Urnov said. With this kind of genetic editing, scientists could inadvertently make a change to a patient's DNA that is off-target, and the therapy could harm the patient. [...] The FDA is expected to make an approval decision by December 8.

"To celebrate my life, I've arranged to buy up others' medical debt and then destroy the debt," reads a posthumous tweet posted Tuesday after the death of 38-year-old Casey McIntyre.

The Washington Post explains... McIntyre, who served as publisher at Razorbill, an imprint of Penguin Random House, was diagnosed in 2019 and proceeded through treatment without taking on debt, [husband Andrew Rose] Gregory told The Washington Post. But many fellow cancer patients she met were in more precarious financial positions, Gregory added. "We were both so keenly aware that Casey had great health insurance through Penguin Random House," said Gregory, 41. "Casey had no medical debt...."

About nine months before McIntyre died, her husband came across a video online about members of a North Carolina church who purchased nearly $3.3 million of local residents' medical debt for $15,048 in a "debt jubilee," a historical reference to ancient stories about personal debts being canceled at regular intervals. The couple chose to make monthly donations to RIP Medical Debt, the same organization that partnered with the North Carolina churchgoers. The nonprofit organization aims to abolish medical debt "at pennies on the dollar," according to its website. For every $100 donated, the company relieves $10,000 of medical debt. As of Saturday, nearly $200,000 had been donated to RIP Medical Debt in McIntyre's memory, which would wipe out approximately $20 million of unpaid medical bills. [By Sunday afternoon it had risen to over $334,000...]

Allison Sesso, president and chief executive of RIP Medical Debt, said her organization found out about McIntyre's case after McIntyre's posthumous social media post went viral. Sesso said the pace of donations was record-setting for her charity. "What an incredible gesture to the world as you're exiting," Sesso told The Post. "This final act of generosity is blowing up. The amount that they're raising and the rate at which this has gone is not something that we're used to."
McIntyre's post on X has now received 65,400 likes — and 3,086 reposts.

According to a new study published in JAMA Internal Medicine, women in the U.S. are now projected to live about six years longer than U.S. men. TIME reports: [T]he 2021 data represent the largest gender-based life expectancy gap in the U.S. since 1996. The gulf began to widen before the COVID-19 pandemic, the authors note, but the trend accelerated from 2019 to 2021. Deaths from COVID-19 and unintentional injuries, a category that includes accidental drug overdoses, were the largest contributors to the widening of the gap, but differential rates of homicide, heart disease, and suicide deaths also played a role, according to the report. It's well-established that men die of these causes more frequently than women, and in recent years, they have been some of the most common causes of death overall. Heart disease, COVID-19, and unintentional injuries accounted for three of the top five in 2021.

The gender gap would have been even wider, the authors note, but for factors including increases in maternal mortality and decreases in cancer deaths among men. Overall, the data underscore the continued importance of limiting COVID-19's spread, and of finding better ways to improve national mental health and prevent drug overdoses and suicides -- fatalities sometimes labeled by experts as "deaths of despair."

Doctors have long relied on a few key patient characteristics to assess risk of a heart attack or stroke, using a calculus that considers blood pressure, cholesterol, smoking and diabetes status, as well as demographics: age, sex and race. Now, the American Heart Association is taking race out of the equation. From a report: The overhaul of the widely used cardiac-risk algorithm is an acknowledgment that, unlike sex or age, race identification in and of itself is not a biological risk factor. The scientists who modified the algorithm decided from the start that race itself did not belong in clinical tools used to guide medical decision making, even though race might serve as a proxy for certain social circumstances, genetic predispositions or environmental exposures that raise the risk of cardiovascular disease.

The revision comes amid rising concern about health equity and racial bias within the U.S. health care system, and is part of a broader trend toward removing race from a variety of clinical algorithms. "We should not be using race to inform whether someone gets a treatment or doesn't get a treatment," said Dr. Sadiya Khan, a preventive cardiologist at Northwestern University Feinberg School of Medicine, who chaired the statement writing committee for the American Heart Association, or A.H.A. The statement was published on Friday [PDF] in the association's journal, Circulation. An online calculator using the new algorithm, called PREVENT, is still in development.

Britain's drugs regulator has approved a groundbreaking treatment for two painful and debilitating lifelong blood disorders, which works by "editing" the gene that causes them. From a report: The Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light for Casgevy to be used to treat sickle cell disease and beta thalassemia. It is the first medicine licensed anywhere that works by deploying gene editing that uses the "genetic scissors," known as CRISPR, for which its inventors won the Nobel prize for chemistry.

Casgevy's developers hope the pioneering treatment could banish the pain, infections and anaemia sickle cell disease brings and the severe anaemia experienced by those with beta thalassemia. About 15,000 people in the UK, almost all of African or Caribbean heritage, have sickle cell disease. About 1,000 -- mainly of Mediterranean, south Asian, south-east Asian and Middle Eastern background -- have beta thalassemia and need regular blood transfusions to treat their anaemia. Experts in the illnesses hope Casgevy may be a cure, making it no longer necessary for people with the conditions to have a bone marrow transplant. Until now this has been the only treatment available, even though the body can reject the donor marrow. The Sickle Cell Society welcomed the MHRA's decision as a "historic moment for the sickle cell community" which "offers [them] newfound hope and optimism."

An anonymous reader quotes a report from NBC News: A prolonged decline in male fertility in the form of sperm concentrations appears to be connected to the use of pesticides, according to a study published Wednesday. Researchers compiled, rated and reviewed the results of 25 studies of certain pesticides and male fertility and found that men who had been exposed to certain classes of pesticides had significantly lower sperm concentrations. The study, published Wednesday in Environmental Health Perspectives, included data from more than 1,700 men and spanned several decades. "No matter how we looked at the analysis and results, we saw a persistent association between increasing levels of insecticide and decreases in sperm concentration," said study author Melissa Perry, who is an environmental epidemiologist and the dean of the College of Public Health at George Mason University. "I would hope this study would get the attention of regulators seeking to make decisions to keep the public safe from inadvertent, unplanned impacts of insecticides." [...]

Scientists have long suspected changes to the environment could be contributing, and they've been probing the role of pesticides for decades in studies of animals and in human epidemiology research. The new analysis focuses on two groups of chemicals -- organophosphates and some carbamates -- that are commonly used in insecticides. The researchers looked at data collected from groups of people with exposures to pesticides and others who were not. Most, but not all, of the research centered on exposures in the workplace. The researchers controlled for outside factors that could contribute to lower sperm counts like smoking and age. Perry said researchers aren't sure how pesticides are affecting sperm concentrations and more research will be needed.

It's likely that pesticides are one of many environmental factors that could be contributing to a decline in sperm concentrations. The trend of sperm concentration declines has been widely observed in studies around the world, but it's a complicated topic and some scientists still have reservations. Sperm are notoriously difficult to count and the technology to do so has changed over the years. There are many confounding factors that can affect male fertility, including age, obesity and opioid use, to name a few. Sperm concentrations are one important data point to consider, but other factors -- like how sperm are shaped and how they swim -- are also critical to male fertility. Perry said she hopes agencies like the Environmental Protection Agency begin to factor the impact of chemicals and pesticides on reproductive health in their assessments. "Given the body of evidence and these consistent findings, it's time to proactively reduce these insecticide exposures for men wanting to have families," Perry said.

Amazon said on Wednesday that it was removing seven eyedrops products from its website after the Food and Drug Administration warned the company that the eyedrops had not been recognized as safe and effective. From a report: The F.D.A. said in a letter to Andrew Jassy, Amazon's chief executive, on Monday that Amazon had violated federal regulations by selling the eyedrops, which claimed to help with problems including pink eye, dry eyes, eyestrain and floaters. "These products are especially concerning from a public health perspective," the F.D.A. letter said. "Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body's natural defenses."

The eyedrops named in the letter are: Similasan Pink Eye Relief, The Goodbye Company Pink Eye, Can-C Eye Drops, Optique 1 Eye Drops, OcluMed Eye Drops, TRP Natural Eyes Floaters Relief, and Manzanilla Sophia Chamomile Herbal Eye Drops. None of the eyedrops appeared to be available for purchase on Amazon on Wednesday morning. The company said in an emailed statement on Wednesday that "safety is a top priority."

AI could be used to predict if a person is at risk of having a heart attack up to 10 years in the future, a study has found. From a report: The technology could save thousands of lives while improving treatment for almost half of patients, researchers at the University of Oxford said. The study, funded by the British Heart Foundation (BHF), looked at how AI might improve the accuracy of cardiac CT scans, which are used to detect blockages or narrowing in the arteries.

Prof Charalambos Antoniades, chair of cardiovascular medicine at the BHF and director of the acute multidisciplinary imaging and interventional centre at Oxford, said: "Our study found that some patients presenting in hospital with chest pain -- who are often reassured and sent back home -- are at high risk of having a heart attack in the next decade, even in the absence of any sign of disease in their heart arteries. Here we demonstrated that providing an accurate picture of risk to clinicians can alter, and potentially improve, the course of treatment for many heart patients."

About 350,000 people in the UK have a CT scan each year but, according to the BHF, many patients later die of heart attacks due to their failure in picking up small, undetectable narrowings. Researchers analysed the data of more than 40,000 patients undergoing routine cardiac CT scans at eight UK hospitals, with a median follow-up time of 2.7 years. The AI tool was tested on a further 3,393 patients over almost eight years and was able to accurately predict the risk of a heart attack. AI-generated risk scores were then presented to medics for 744 patients, with 45% having their treatment plans altered by medics as a result.

There's already a powerful immunotherapy that "involves engineering a patient's T cells so they recognize and attack cancer cells," writes one of America's top cancer hospitals. The Memorial Sloan Kettering Cancer Center notes that CAR T cell therapy has already begun to revolutionize cancer treatment," with these "chimeric" T cells "multiplied in a lab and given back to the patient to be a continual fighting force against the cancer."

But now "New research from the lab of physician-scientist Michel Sadelain, MD, PhD, shows that disrupting a single gene in the CAR T cells can make them more potent and able to fight tumors longer." In a paper published in Cancer Discovery, the team demonstrated that disrupting the gene SUV39H1 causes a ripple effect: It restores the expression of multiple genes that help sustain the T cells' longevity. The researchers showed that this approach improved CAR T cell effectiveness against multiple cancers in mice...

The researchers used the gene-editing tool CRISPR/Cas9 to alter SUV39H1 in human CAR T cells. They placed these modified CAR T cells into mice that had been implanted with either human leukemia cells or prostate cancer cells. For both cancers, the CAR T cells were able to sustain their function without becoming exhausted, leading to tumor elimination. By contrast, mice with unedited CAR T cells did not survive the cancer. "The edited CAR T cells can maintain their anti-cancer effects, even when we challenged them repeatedly by exposing them to new tumors over time," Dr. Zhao says. "These results suggest that SUV39H1-edited CAR T cells may reduce tumor relapse in patients."

There did not appear to be serious side effects in the mice, although researchers will need to confirm the safety of this approach in humans. The biotechnology company Mnemo Therapeutics is exploring the possibility of conducting clinical trials based on this research.

Cells have a protein receptor that will cause that cell to die — in theory. Unfortunately, "Previous efforts to target this receptor have been unsuccessful," says Jogender Tushir-Singh, an associate professor in the Department of Medical Microbiology and Immunology at the University of California, Davis.

But he's now led a team of researchers at the university's Comprehensive Cancer Center that's identified a receptor-activating protein section. And more importantly, "now that we've identified this epitope, there could be a therapeutic path forward" for targeting that receptor... in tumors. The findings were published Oct. 14 in the Nature journal Cell Death & Differentiation... Death receptors do precisely what their name implies — when targeted, they trigger programmed cell death of tumor cells. They offer a potential workaround that could simultaneously kill tumor cells and pave the way for more effective immunotherapies and CAR T-cell therapy...

Tushir-Singh and his colleagues knew they might be able to target cancer cells selectively if they found the right epitope. Having identified this specific epitope, he and other researchers can now design a new class of antibodies to selectively bind to and activate Fas to potentially destroy tumor cells specifically.
Singh says their research "sets the stage" to develop antibodies that selectively kill tumor cells.

A new book argues lockdowns during the pandemic were "a failure." But in response CNN published an opinion piece disagreeing — written by physician/infectious disease expert Kent Sepkowitz from the Memorial Sloan Kettering Cancer Center in New York — who argues "You bet it was worth it." [Authors Joe Nocera and Bethany McLean] consider the lockdown a single activity stretched across the entire pandemic; in contrast, I would distinguish the initial lockdown, which was crucial, from the off-and-on lockdowns as therapies, vaccines and overall care improved. There is an argument to be made that these were not anywhere near as effective... One only had to work in health care in New York City to see the difference between early 2020, when the explosion of cases overwhelmed the city, versus later in 2020 when an effective therapy had been identified, supplies and diagnostic testing had been greatly improved (though still completely inadequate) and the makeshift ICUs and emergency rooms had been set in place. It was still a nightmare to be sure, but it was a vastly more organized nightmare.

The "short-term benefits" at the start of the pandemic are simple to characterize: Every infection that was delayed due to the lockdowns was a day to the good, a day closer to the release of the mRNA vaccines in December 2020, a less-hectic day for the health care workers, a day for clinical trials to mature. Therefore, the authors' statement that lockdowns "were a mistake that should not be repeated" because they had no "purpose other than keeping hospitals from being overrun in the short-term" is to me a fundamental misunderstanding of the day-to-day work that was being done. Most disturbing to me about this assessment and the others that have come along are the minimal mention of the death and debility the infection caused. A reminder for those who have forgotten just how brutal the pandemic was: Worldwide there have been 7 million deaths. In the U.S., there have been more than a million deaths, millions have some post-infection debility and many health care workers remain profoundly demoralized. [By these figures the U.S., with 4.2% of the world's population, had 14% of Covid fatalities.]

In this context, many of the outcomes of concern listed by Nocera and McLean — suicidal thoughts in teens, alcoholism and drug use increases, violence — are as easily explained by this staggering death toll as by the cabin fever brought on by lockdowns. Once again: About 1 out of every 350 Americans died in the Covid-19 pandemic. Another way to consider the impact of so many deaths is examination of life expectancy. Of note, life expectancy in the U.S. fell in 2020 (1.8 years) and 2021 (0.6 years), the sharpest drop since the 1920s; per the US Centers for Disease Control and Prevention, 74% of the drop was attributed to Covid-19... To fall more than two years so precipitously requires the deaths of many in their 30s and 40s and 50s, as occurred with the first year of the pandemic.

An anonymous reader quotes a report from Scientific American: This week doctors announced they had completed the first successful transplant of a partial face and an entire eye. In May at NYU Langone Health in New York City, the surgery was performed on a 46-year-old man who had suffered severe electrical burns to his face, left eye and left arm. He does not yet have vision in the transplanted eye and may never regain it there, but early evidence suggests the eye itself is healthy and may be capable of transmitting neurological signals to the brain. The feat opens up the possibility of restoring the appearance -- and maybe even sight -- of people who have been disfigured or blinded by injuries. Researchers caution there are many technical hurdles before such a procedure can effectively treat vision loss, however.

"I think it's an important proof of principle," says Jeffrey Goldberg, a professor and chair of ophthalmology at the Byers Eye Institute at Stanford University, who was not involved in the surgery but has been part of a team working toward whole-eye transplants in humans. "I think it points to the opportunity and importance that we really stand on the verge of being able to [achieve] eye transplants and vision restoration for blind patients more broadly."But he cautions that the main obstacle is achieving regeneration of the optic nerve, which carries visual signals from the retina to the brain; this step has not yet been successfully demonstrated in humans.

Scientists have been working toward whole-eye transplantation for many years. "This has been, I would say, science fiction for a long time," says Jose-Alain Sahel, a professor and chair of the department of ophthalmology at the University of Pittsburgh School of Medicine, who has been working toward such transplants with Goldberg and others. Progress in surgical techniques and nerve regeneration have made this goal seem more attainable. [...] "The fact that this surgery was successful is wonderful news," Sahel says. He cautions that surgery is only a small part of the issues that need to be addressed in order to restore eye function, however. These include making sure the immune system doesn't reject the donor eye, which is a challenge with any type of transplant. Then the corneal nerve -- which carries sensory signals from the transparent part of the eye -- must be reconnected. Yet the most complex part is regenerating the optic nerve. In order to do so, surgeons have to coax the nerve fibers to grow to the right place, which Sahel says could take months or even years. And complete optic nerve regeneration has not yet been successfully achieved in humans or other mammals.

Long-time Slashdot reader Alain Williams writes: Apple co-founder Steve Wozniak is in the hospital in Mexico, according to multiple reports.

It is not currently clear what the cause is. The 73-year-old was in Mexico City attending the World Business Forum (WBF), a business conference. [According to TMZ, Wozniak finished his speech but then told his wife he was "feeling strange." She reportedly insisted he go to the hospital.] An unnamed source from the WBF said that Mr Wozniak fainted on Wednesday at the event [minutes before his participation], according to CNN. TMZ reports that Wozniak was hospitalized after "suffering what appears to be vertigo." Mexican media outlets were reporting that it was due to a possible stroke.

An anonymous reader quotes a report from the Financial Times: Amazon Prime members will be able to access US healthcare provider One Medical's suite of benefits, for a fee, as the ecommerce company looks to expand its presence in the $4 trillion American healthcare industry. Prime members in the US who opt in will have access to unlimited, on-demand virtual healthcare via One Medical, the subscription-based group that Amazon acquired last year for $3.9 billion. They will also be able to schedule in-person appointments that they will either pay for themselves or that will be covered by insurance.

The addition to Amazon's flagship Prime membership program comes as the company looks to "stack" healthcare services together and broaden its reach in the sector, which would be "big for us if we do a good job," said Neil Lindsay, senior vice-president of Amazon Health. The subscription will cost Amazon Prime members $9 per month or $99 per year, compared with the standard One Medical subscription fee of $199 per year. That will come on top of the $139 per year, or $14.99 a month, price for a Prime subscription.

The move is Amazon's latest effort to leverage its loyal base of Prime members and become a big player in the healthcare industry. In January, following its 2018 acquisition of mail-order pharmacy PillPack for about $1 billion, Amazon launched RxPass, which allows Prime members to order an unlimited amount of some unbranded prescription medications for $5 a month. It has also rolled out a "Clinic" telehealth service that connects patients with clinicians and a broader mail-order pharmacy service.

The scientific literature is polluted with fake manuscripts churned out by paper mills -- businesses that sell bogus work and authorships to researchers who need journal publications for their CVs. But just how large is this paper-mill problem? From a report: An unpublished analysis shared with Nature suggests that over the past two decades, more than 400,000 research articles have been published that show strong textual similarities to known studies produced by paper mills. Around 70,000 of these were published last year alone. The analysis estimates that 1.5-2% of all scientific papers published in 2022 closely resemble paper-mill works. Among biology and medicine papers, the rate rises to 3%.

Without individual investigations, it is impossible to know whether all of these papers are in fact products of paper mills. But the proportion -- a few per cent -- is a reasonable conservative estimate, says Adam Day, director of scholarly data-services company Clear Skies in London, who conducted the analysis using machine-learning software he developed called the Papermill Alarm. In September, a cross-publisher initiative called the STM Integrity Hub, which aims to help publishers combat fraudulent science, licensed a version of Day's software for its set of tools to detect potentially fabricated manuscripts.

Paper-mill studies are produced in large batches at speed, and they often follow specific templates, with the occasional word or image swapped. Day set his software to analyse the titles and abstracts of more than 48 million papers published since 2000, as listed in OpenAlex, a giant open index of research papers that launched last year, and to flag manuscripts with text that very closely matched known paper-mill works. These include both retracted articles and suspected paper-mill products spotted by research-integrity sleuths such as Elisabeth Bik, in California, and David Bimler (also known by the pseudonym Smut Clyde), in New Zealand.